Sangamo Therapeutics (SGMOQ) Asset Writedowns and Impairment (2015 - 2025)

Sangamo Therapeutics has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $13.2 million in Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $13.2 million in Q4 2025; TTM through Dec 2025 was $13.2 million, a 139.72% increase from a year earlier, with the FY2025 full-year figure at $13.2 million, up 139.72% from the prior year.
• Asset Writedowns and Impairment was $13.2 million for Q4 2025 at Sangamo Therapeutics, up from $1.2 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $51.3 million in Q2 2023, with the low at $200000.0 in Q4 2023.
• Average Asset Writedowns and Impairment over 3 years is $21.9 million, with a median of $13.2 million recorded in 2025.
• The largest YoY upside for Asset Writedowns and Impairment was 88.6% in 2024 against a maximum downside of 97.72% in 2024.
• Over 3 years, Asset Writedowns and Impairment stood at $200000.0 in 2023, then jumped by 486.0% to $1.2 million in 2024, then jumped by 1029.27% to $13.2 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $13.2 million (Q4 2025), $1.2 million (Q2 2024), and $4.3 million (Q1 2024), per Business Quant data.